secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0001213900-24-031716
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma posts investor presentation; EB103 Phase I expected 1H 2024
--------------------------------------------------------------------------------

- EB103 (CD19 ARTEMIS) IND cleared Q1 2023; Phase I trial targeted for 1H 2024 in r/r B-cell lymphoma.
- IIS study: 6/12 CR (50%), 4/12 PR (33%), ORR 83%; no severe CRS; durable responses up to 23.2 months.
- Partnered with Imugene (ASX:IMU) to combine CF33-CD19t oncolytic virus with EB103 for solid tumors.
- Pipeline includes EB104 (CD19/CD22 dual-targeting) for lymphoma and EB201 for SLE (preclinical).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024031716/0001213900-24-031716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024031716/ea0203610-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-031716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer